Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Standard BioTools Inc.
13D/A
Amendment 8
LAB · 34385P108
|
23.9% |
6/9/2026
Event 6/6/2026
|
|||
| Casdin Capital, LLC | 22.7% | ||||
| Casdin Private Growth Equity Fund II, L.P. | 3.6% | ||||
| Casdin Private Growth Equity Fund II GP, LLC | 3.6% | ||||
| Casdin Partners Master Fund, L.P. | 18.5% | ||||
| Casdin Partners GP, LLC | 18.5% | ||||
| Eli Casdin | 23.9% | ||||
|
Biolife Solutions Inc
13G
BLFS · 09062W204
|
9.7% |
6/4/2026
Event 6/4/2026
|
|||
| Casdin Capital, LLC | 9.7% | ||||
| Casdin Partners Master Fund, L.P. | 9.7% | ||||
| Casdin Partners GP, LLC | 9.7% | ||||
| Eli Casdin | 9.7% | ||||
|
Biolife Solutions Inc
13D/A
Amendment 7
BLFS · 09062W204
|
9.7% |
5/22/2026
Event 5/20/2026
|
|||
| Casdin Capital, LLC | 9.7% | ||||
| Casdin Partners Master Fund, L.P. | 9.7% | ||||
| Casdin Partners GP, LLC | 9.7% | ||||
| Eli Casdin | 9.7% | ||||
|
Relay Therapeutics, Inc.
13G/A
Amendment 2
RLAY · 75943R102
|
7.5% |
2/17/2026
Event 12/31/2025
|
|||
| Casdin Capital, LLC | 7.5% | ||||
| Casdin Partners Master Fund, L.P. | 7.3% | ||||
| Casdin Partners GP, LLC | 7.5% | ||||
| Eli Casdin | 7.5% | ||||
|
Relay Therapeutics, Inc.
13G/A
Amendment 2
RLAY · 75943R102
|
7.5% |
2/17/2026
Event 12/31/2025
|
|||
| Casdin Capital, LLC | 7.5% | ||||
| Casdin Partners Master Fund, L.P. | 7.3% | ||||
| Casdin Partners GP, LLC | 7.5% | ||||
| Eli Casdin | 7.5% | ||||
|
Standard BioTools Inc.
13D/A
Amendment 7
LAB · 34385P108
|
24.2% |
11/28/2025
Event 11/25/2025
|
|||
| Casdin Capital, LLC | 22.9% | ||||
| Casdin Private Growth Equity Fund II, L.P. | 3.6% | ||||
| Casdin Private Growth Equity Fund II GP, LLC | 3.6% | ||||
| Casdin Partners Master Fund, L.P. | 18.7% | ||||
| Casdin Partners GP, LLC | 18.7% | ||||
| Eli Casdin | 24.2% | ||||
|
Codexis, Inc.
13G/A
Amendment 2
CDXS · 192005106
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Casdin Capital, LLC | 0% | ||||
| Casdin Partners Master Fund, L.P. | 0% | ||||
| Casdin Partners GP, LLC | 0% | ||||
| Eli Casdin | 0% | ||||
|
BioLife Solutions, Inc.
13D/A
Amendment 6
BLFS · 09062W204
|
12.4% |
10/17/2025
Event 10/15/2025
|
|||
| Casdin Capital, LLC | 12.4% | ||||
| Casdin Partners Master Fund, L.P. | 12.4% | ||||
| Casdin Partners GP, LLC | 12.4% | ||||
| Eli Casdin | 12.4% | ||||
|
BioLife Solutions, Inc.
13D/A
Amendment 5
BLFS · 09062W204
|
14.0% |
8/21/2025
Event 8/15/2025
|
|||
| Casdin Capital, LLC | 14.0% | ||||
| Casdin Partners Master Fund, L.P. | 14.0% | ||||
| Casdin Partners GP, LLC | 14.0% | ||||
| Eli Casdin | 14.0% | ||||
|
Codexis, Inc.
13G/A
Amendment 1
CDXS · 192005106
|
8.7% |
8/14/2025
Event 6/30/2025
|
|||
| Casdin Capital, LLC | 8.7% | ||||
| Casdin Partners Master Fund, L.P. | 8.7% | ||||
| Casdin Partners GP, LLC | 8.7% | ||||
| Eli Casdin | 8.7% | ||||
|
BioLife Solutions, Inc.
13D/A
Amendment 4
BLFS · 09062W204
|
15.0% |
8/13/2025
Event 8/11/2025
|
|||
| Casdin Capital, LLC | 15.0% | ||||
| Casdin Partners Master Fund, L.P. | 15.0% | ||||
| Casdin Partners GP, LLC | 15.0% | ||||
| Eli Casdin | 15.0% | ||||
|
BioLife Solutions, Inc.
13D/A
Amendment 3
BLFS · 09062W204
|
16.2% |
6/12/2025
Event 6/10/2025
|
|||
| Casdin Capital, LLC | 16.2% | ||||
| Casdin Partners Master Fund, L.P. | 16.2% | ||||
| Casdin Partners GP, LLC | 16.2% | ||||
| Eli Casdin | 16.2% | ||||
|
Century Therapeutics, Inc.
13G/A
Amendment 1
IPSC · 15673T100
|
3.7% |
5/15/2025
Event 3/31/2025
|
|||
| Casdin Capital, LLC | 3.7% | ||||
| Eli Casdin | 3.7% | ||||
|
BioLife Solutions, Inc.
13D/A
Amendment 2
BLFS · 09062W204
|
18.5% |
4/9/2025
Event 4/7/2025
|
|||
| Casdin Capital, LLC | 18.5% | ||||
| Casdin Partners Master Fund, L.P. | 18.5% | ||||
| Casdin Partners GP, LLC | 18.5% | ||||
| Eli Casdin | 18.5% | ||||
|
Tenaya Therapeutics, Inc.
13D/A
Amendment 3
TNYA · 87990A106
|
4.3% |
3/7/2025
Event 3/4/2025
|
|||
| Casdin Capital, LLC | 4.3% | ||||
| Casdin Partners Master Fund, L.P. | 4.1% | ||||
| Casdin Partners GP, LLC | 4.1% | ||||
| Eli Casdin | 4.3% | ||||
|
Standard Biotools Inc.
13D/A
Amendment 6
LAB · 34385P108
|
21.6% |
3/4/2025
Event 2/28/2025
|
|||
| Casdin Capital, LLC | 20.4% | ||||
| Casdin Private Growth Equity Fund II, L.P. | 3.7% | ||||
| Casdin Private Growth Equity Fund II GP, LLC | 3.7% | ||||
| Casdin Partners Master Fund, L.P. | 15.9% | ||||
| Casdin Partners GP, LLC | 15.9% | ||||
| Eli Casdin | 21.6% | ||||
|
Neurogene Inc.
13G/A
Amendment 1
NGNE · 64135M105
|
8.7% |
2/14/2025
Event 12/31/2024
|
|||
| Casdin Capital, LLC | 8.7% | ||||
| Casdin Partners Master Fund, L.P. | 7.2% | ||||
| Casdin Partners GP, LLC | 7.2% | ||||
| Eli Casdin | 8.7% | ||||